Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 807-747-9 | CAS number: 144429-84-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
No carcinogenicity was observed in feeding studies with rats and mice (Huntingdon, 1974 and Ciba-Geigy, 1982) performed similar to OECD testing guidelines 453 and 451, respectively. Both studies were performed with an analogue substance.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 451 (Carcinogenicity Studies)
- Deviations:
- yes
- Principles of method if other than guideline:
- No report on analytical procedures and results. No analysis of the lowest dose level. No analysis of homogeneity of the initial preparation.
- GLP compliance:
- no
- Species:
- mouse
- Strain:
- other: Tif: MAGf
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Animal Production Stein, CIBA-GEIGY LTD.
- Age at study initiation: approx. 4 weeks
- Mean group weight at study initiation: 21.1-21.5 g (males), 20.3-20.8 g (females)
- Housing: 5 per cage
- Diet (e.g. ad libitum): Pelleted, certified standard diet Nafag No. 890 Tox
- Water (e.g. ad libitum): tap water
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2
- Humidity (%): 55±10
- Air changes (per hr): 15-17
- Photoperiod (hrs dark / hrs light): 10 - Route of administration:
- oral: feed
- Details on exposure:
- DIET PREPARATION
- the test item was weighed on a calibrated Mettler balance. The pulverised food was then homogeneously mixed with the appropriate concentrations of the compound and 30 % water was added before pelleting to ensure the necessary pellet quality. The pellets were subsequently airdried. The animals in the control group were fed with similarly pelleted food without compound. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Prior to the initiation of the study pretest feed samples were analysed for concentration and stability of the test material. The same was undertaken with the food batches applied during the test. The analytical results revealed a concentration of 82-95 % of the nominal value. The analytical results of the diet of the lowest dose groups (5 mg/kg feed) are not available for technical reasons: The limit of detection was at 5 to 10 mg/kg feed.
- Duration of treatment / exposure:
- 24 months
- Frequency of treatment:
- continously
- Post exposure period:
- none
- Dose / conc.:
- 5 mg/kg diet
- Remarks:
- corresponding to 0.6 mg/kg in males and females
- Dose / conc.:
- 50 mg/kg diet
- Remarks:
- corresponding to 5.4 mg/kg in males and females
- Dose / conc.:
- 500 mg/kg diet
- Remarks:
- corresponding to 58 mg/kg in males and 54 mg/kg in females
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
- Cage side observations: symptoms, mortality
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly, after 3 months monthly
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated: Yes - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
- Macroscopic: complete gross examination
- Microscopic: adrenals, aorta, bone marrow, brain, caecum, colon, duodenum, epididymis, eyes, gall bladder, heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes (axillary and mesenteric), oesophagus, ovaries, pancreas, pituitary, prostate, rectum, salivary gland, sciatic nerve, seminal vesicles, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urinary bladder and uterus, and all nodules, tissue masses and otherwise macroscopically abnormal tissues. - Other examinations:
- Liver, adrenals, brain, heart, kidneys and gonads were weighed.
- Statistics:
- - Uni-variate statistical comparison of the treatment group with control group (Lapage Y., Biometrika 1971) and a Trend test (Jonckheere H.R., Biometrika, 1954) considering all groups.
- Generalised Wilcoxon Test (Breslown., Biometrika, 1970)
- Generalised Savage Test (Mantel-Cox, Cancer Chemotherapy Reports 1966, 50: pp. 163-170) - Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical symptoms and no signs of local and/or systemic toxicity were observed.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- The highest dose group of treated males and females showed a tendency to shortened survival time compared to the respective control group (males: 583 Vs 695 in controls; females: 667 Vs 709 in controls), however not significant.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The mean body weight gain in all treated male and female groups was similar to that of the respective control groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The mean food consumption of all treated male and female groups was similar to that of the respective control groups. Based on the nominal value the mean daily intake in male and female of 5 mg/kg-feed group was 0.6 mg/kg bw. Corrected for the actual amount of substance, found by chemical analysis, the dose in 50 and 500 mg/kg- feed groups was 5.4 and 58 mg/kg bw in males and 5.4 and 54 mg/kg bw in female animals, respectively.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- Specific food consumption in relation to body weight - adressed as food conversion ratio - of all treated animal groups was similar to that of the respective control groups.
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- The analysis of organ weights and organ weight ratios revealed no treatment related effects.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No gross changes in the organs and tissues related to the treatment were noted.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No microscopic changes in the organs and tissues related to the treatment were noted.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- Numerous benign and malignant tumours were observed in both control and treated mice. Frequency and type of the neoplasms occurring in these animals were not influenced by the treatment.
- Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 58 mg/kg bw/day (actual dose received)
- Sex:
- male
- Basis for effect level:
- other: carcinogenicity
- Remarks on result:
- other: highest dose tested
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 54 mg/kg bw/day (actual dose received)
- Sex:
- female
- Basis for effect level:
- other: carcinogenicity
- Remarks on result:
- other: highest dose tested
- Key result
- Critical effects observed:
- no
- Conclusions:
- No systemic toxicity or microscopic changes in the organs and tissues were observed. The only effect observed was the shorter survival time in the animals of highest dose group. Thus, the NOAEL for carcinogenicity was considered to be ≥ 54 and 58 mg/kg bw/d for the female and male animals, respectively. The test substance does not require any classification for carcinogenicity according to EU or GHS standards.
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Comparable to guideline, without GLP (acceptable with restrictions); No GLP study - Limited haematology, biochemistry and urinalysis only on the control and high dose groups instead of all groups - No analysis of the accuracy of preparation of the diet were reported. Actual test article intake only calculated values - No historical data included
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- yes
- Principles of method if other than guideline:
- - No GLP study
- Limited haematology, biochemistry and urinalysis only on the control and high dose groups instead of all groups
- No analysis of the accuracy of preparation of the diet were reported. Actual test article intake only calculated values
- No historical data included. - GLP compliance:
- no
- Species:
- rat
- Strain:
- other: CFY
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Carworth Europe, England
- Age at study initiation: 27 ± 1 days
- Mean weight at study initiation: male 123 g, female 103 g (differing from one another by no more than ± 2.5 g)
- Housing: 5 per cage
- Diet (e.g. ad libitum): powdered laboratory rat food (Spratt's Laboratory)
- Water (e.g. ad libitum): tap water
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21±2
- Humidity (%): 55±5
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: feed
- Details on exposure:
- DIET PREPARATION
- A premix containing 30000 ppm was prepared each week, and from this the different dietary concentrations were obtained by direct dilution with further quantities of diet. Homogeneity was achieved by mixing for ten minutes in a rotary double-cone blender; all diets were stored until use in heat-sealed, opaque polythene bags. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of the diets fed to the rats have been analysed for their content of the test item by a thin layer chromatographic method.
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- continously
- Post exposure period:
- none
- Dose / conc.:
- 500 ppm (nominal)
- Remarks:
- corresponding to 22 mg/kg in males and 27 mg/kg in females
- Dose / conc.:
- 1 500 ppm (nominal)
- Remarks:
- corresponding to 64 mg/kg in males and 81 mg/kg in females
- Dose / conc.:
- 5 000 ppm (nominal)
- Remarks:
- corresponding to 218 mg/kg in males and 275 mg/kg in females
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
- Cage side observations: mortality, all signs of ill-health and toxicity, together with any behavioural changes. Detailed descriptions were made of any skin lesions, cataracts or palpable growths, together with the progression or regression of such lesions.
BODY WEIGHT: Yes
- Time schedule for examinations: initially, then at weekly intervals for the first twelve weeks and at four-weekly intervals thereafter
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE: Yes,assessed in the first instance by inspection of the water bottles
- Time schedule for examinations: Accurate measurement of water intake was introduced during week 37 since a treatment-related effect on water consumption was suspected
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Before treatment commenced, and after 13, 26, 52, 75 and 102 weeks
- Dose groups that were examined: control and 5000 ppm groups
HAEMATOLOGY: Yes
- Time schedule for collection of blood: After 13, 26, 52, 78 and 103 weeks of treatment
- Anaesthetic used for blood collection: samples of blood were withdrawn from the orbital sinus
- How many animals: 10 males and 10 females from control and 5000 ppm groups
- Parameters checked: Packed cell volume (PCV), Haemoglobin (Hb), Red cell count (RBC), Mean corpuscular haemoglobin concentration (MCHC), mean cell volume (MCV), Total white cell count (WBC), Differential count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: After 13, 26, 52, 78 and 103 weeks of treatment
- How many animals: 10 males and 10 females from control and 5000 ppm groups
- Parameters checked: Plasma Urea nitrogen, Plasma Glucose, Serum alkaline phosphatase (SAP), Serum glutamic-pyruvic transaminase (SGPT)
URINALYSIS: Yes
- Time schedule for collection of urine: After 13, 26, 52, 78 and 103 weeks of treatment
- Parameters checked: pH, Specific gravity (SG), Protein, Reducing substances, Glucose, Ketones, Bile pigments, Urobilin, Blood pigments, Microscopy (examined for epithelial cells, polymorphonuclear leucocytes, mononuclear leucocytes, erythrocytes, organisms, casts, abnormal constituents) - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
- Macroscopic: complete gross examination
- Microscopic: adrenals, aorta, brain, caecum, colon, duodenum, eyes, femur, heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes (cervical and mesenteric), optic nerve, ovaries, pancreas, pituitary, prostate, rectum, sciatic nerve, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, urinary bladder and uterus, and all nodules, tissue masses and otherwise macroscopically abnormal tissues. Examinations were performed in decedents and 10 males and 10 females from the control group and 5000 ppm group. - Other examinations:
- The weights of the following organs were recorded: adrenals, kidneys, pituitary, brain, liver, spleen, heart, testes, thyroid
- Statistics:
- Student's 't' test was employed to assess the significance of intergroup differences where the data suggested a treatment-related effect.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no overt signs of reaction to treatment.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- The survival rates among treated rats were comparable with those of the controls, with the exception of females exposed at 5000 ppm where a marginally superior survival (33 vs 23 in control) was recorded during the 104 week treatment period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Although a superior rate of bodyweight gain was recorded during weeks 24 to 52 and weeks 80 to 104 among males treated at 1500 ppm, the apparent effect was not dosage related and, therefore, was not considered to be of toxicological significance. Bodyweight gain of other treated males was comparable with that of the controls. Females receiving 5000 ppm had an inferior bodyweight gain throughout the treatment period, although the difference from the control value was not statistically significant after week 52. Bodyweight gain of other treated females was comparable with that of the confrols.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A reduction in food intake was recorded among female rats receiving 5000 ppm during the 104 week treatment period and among females receiving 1500 ppm during the first 80 weeks of freatment. During weeks 53 to 80, a significant reduction in food intake was recorded among all male and female treated rats, although among freated males there was no evidence of a dosage relation. The mean intake of test material (mg/kg bw/day) during the 104 week treatment in males were 22, 64 and 218, respectively, and in females were 27, 81, 275, respectively.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- The efficiency of food utilization among male rats was not disturbed by treatment during the period of fastest growth, i.e. weeks 1 to 24. Among female rats receiving 5000 ppm, a minor impairment of the efficiency of food utilization was recorded during weeks 9 to 16 and 21 to 24. There was, however, no marked overall between-group difference in the efficiency of food utilization among female rats during the period of fastest growth.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- As the water intake of male and female rats during 37 receiving 5000 ppm was found to be closely comparable with that of the confrols, further measurements were not performed.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No changes attributable to treatment were observed.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- At the week 13 investigation, a small decrease in the mean haemoglobin value was recorded for male rats receiving 5000 ppm (P<0.01) and a small increase in the mean cell volume (MCV) among female rats receiving the same dosage (P<0.01). No statistically significant between-group differences were observed at the 26 week investigation. At week 52, male rats receiving 5000 ppm showed a small increase in the total white blood cell count (P<0.05) with an increase in the neutrophil value, attaining a level of statistical significance (P<0.05). At week 78 male rats receiving 5000 ppm showed a small decrease in red blood cell count (P<0.001), associated with an increase in the mean cell volume (MCV), (P<0.01), and a small decrease in the total white cell count (P<0.05) with a decrease in the lymphocyte value attaining a level of statistical significance (P<0.05). A small decrease in the mean cell volume (P<0.05) was recorded among female rats receiving 5000 ppm. No statistically significant between-group differences were observed at the week 103 investigations with the exception of a small increase in mean cell volume (MCV) among females receiving 5000 ppm (P<0.05), associated with a marginal, but not statistically significant decrease in red cell count. Since the changes recorded during the course of the study were of a small order of magnitude, lacked consistency in relation to time and sex, and all values were within the normal range for the strain of rat employed, it was considered that the differences were of doubtful biological significance.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- At the 13 and 26 week investigations, rats receiving 5000 ppm showed a small but significant reduction in plasma glucose levels when compared with the control values. (Week 13 - males P<0.05, females P<0.001; week 26 - males and females P<0.05). At week 52, only the females of this group showed glucose values which were significantly different from those of the controls, (P<0.01). At the week 78 investigation, male rats receiving 5000 ppm showed a small reduction in plasma glucose levels (P<0.001), while females treated with the same dosage showed a small increase in plasma glucose levels (P<0.05). Although a level of statistical significance was attained by the marginal difference between SAP levels recorded among controls and treated female rats (P<0.05) the difference was not considered to be biologically significant. No statistically significant between-group differences were recorded at the week 103 investigations.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No changes attributable to treatment were recorded at week 13 and 52. At the 103 week investigations, the only significant between group difference observed was a decrease in the protein in the urine of male (P<0.05) and female (P<0.01) rats compared to control values.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Organ weight analysis performed on rats killed after 104 weeks of treatment revealed heavier absolute liver weight in males treated with 5000 ppm. When expressed relative to bodyweight, males and females treated with 5000 ppm had liver weights heavier than those of the controls. In the absence of any histopathological change, it was considered that these changes probably represent the effect of work hypertrophy. Increased weights of thyroids in rats treated with 5000 ppm and decreased weights of adrenals in females treated with 5000 or 1500 ppm were recorded. As histopathological examination revealed no apparent change, these changes could not be unequivocally attributed to treatment. Due to the uniformity of brain weight recorded in rats employed on this study, expressing the organ weights relative to brain weight resulted in similar differences as recorded in the absolute data. Other small differences in weights of organs from treated rats were attributed to the intergroup disparity in bodyweight and were considered to be of no toxicological significance.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The prime cause of death among rats dying during the course of the study showed no relation to treatment. Macroscopic examination of decedents and rats killed after 104 weeks of treatment showed pathology which was common to animals from control and treated groups.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No morphological abnormalities or variation from normal were seen in any of the tissues examined which was considered to be due to the administration.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- The administration was not associated with any evidence of a tumorigenic effect on the spontaneous tumour incidence of the CFY rat.
- Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 218 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: carcinogenicity
- Remarks on result:
- other: highest dose tested
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 275 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: carcinogenicity
- Remarks on result:
- other: highest dose tested
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 64 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on a reduction of body weight in females and effects on organ weights reported at 5000 ppm in both sexes, the NOAEL is set at 1500 ppm. Effects on organ weights were not taken into account because of the absence of histopathological findings.
- Key result
- Critical effects observed:
- no
- Conclusions:
- No changes attributable to treatment were observed in clinical or biochemical. No non-neoplastic or neoplastic effects were observed in any of the tissues examined. Based on the results, the NOAEL for carcinogenicity was considered to be ≥ 218 mg/kg bw/day (males) and ≥ 275 mg/kg bw/day (females).
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 218 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Valid and reliable study with rats.
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is not considered to be classified for carcinogenicity under Regulation (EC) No 1272/2008, as amended for the eighth timeRegulation (EU) No 2016/218.
Additional information
The read-across substance was tested for its carcinogenic potential in 2 species (rats and mice). Fifty male and 50 female rats per dose group were fed diets containing the test substance (22, 64 and 218 mg/kg bw in males, and 27, 81 and 275 mg/kg bw in females) for 104 weeks. A dietary control group was also included. Similarly mice were fed with the test substance (0.6, 5.4 and 58 mg/kg bw/ day in males; 0.6, 5.4 and 54 mg/kg bw in females) for 104 weeks. Survival in both species was similar to that of controls and no neoplasms were observed.
Summarized, no carcinogenic potential was detected by feeding maximal dose levels tested in both the species.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.